Background--Heart failure (HF) with reduced ejection fraction (rEF) is a widely regarded prognosticator after coronary artery bypass grafting. HF with preserved ejection fraction (pEF) accounts for up to half of all HF cases and is associated with considerable morbidity and mortality in hospitalized cohorts. However, HFpEF outcomes have not been elucidated in cardiac surgical patients. We investigated the prevalence and outcomes of HFpEF and HFrEF in women and men following coronary artery bypass grafting.
H eart failure (HF) is a known complication of coronary artery disease (CAD) that is commonly treated with coronary artery bypass grafting (CABG). HF with reduced ejection fraction (HFrEF) is a widely accepted risk factor for operative and long-term mortality 1, 2 and has been the focus of perioperative screening and optimization. 3, 4 HF with preserved ejection fraction (HFpEF) is nearly as prevalent and fatal as HFrEF 5, 6 but is poorly recognized in the perioperative realm.
The diagnosis of HFpEF is based on the presence of signs and symptoms of HF and left ventricular ejection fraction (EF) of ≥50%. 7 There is regional variability in the prevalence of CAD in patients with HFpEF. 5, 8, 9 In addition, population-based reports suggest that HFpEF can be associated with CAD and is more prevalent in elderly women with a history of hypertension or diabetes mellitus. 10 Despite the importance of HFpEF, 11, 12 its epidemiology has not been elucidated in the diverse ethnic mix of surgical patients in North America, nor have sex-stratified analyses of long-term outcomes of patients with HFpEF who have undergone CABG ever been performed. We investigated the prevalence and prognosis of HFpEF and HFrEF in men and women who underwent CABG in Ontario, Canada, from 2008 to 2015.
Methods Design and Study Population
We conducted a population-based, retrospective cohort study in Ontario, Canada, between October 1, 2008, and March 31, 2015 . The research ethics board of Sunnybrook Health Sciences, Toronto, Canada, approved this study and waived the need for informed consent. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. Included were adult patients 40 years and older who underwent primary isolated CABG in Ontario. We excluded patients who were non-Ontario residents, who had a history of cardiac surgery, or who had missing information regarding age, sex, and left ventricular EF (Figure 1 ). During the study period, Ontario was Canada's most populous province with a public-funded universal healthcare system that reimbursed all healthcare providers and services.
Data Sources
The authors used the registry data of the CorHealth Ontario and population-level administrative healthcare databases with information on all Ontario residents available at the Institute for Clinical Evaluative Sciences (ICES). Individuals who underwent primary isolated CABG were identified from the CorHealth Ontario registry. The CorHealth Ontario registry is a network of 18 hospitals that maintains a detailed prospective clinical registry of all patients who undergo invasive cardiac procedures in Ontario. It captures demographic, comorbidity, and procedural-related information and has been validated through selected chart audits. In addition, CorHealth Ontario registry EF and angiographic data undergo core laboratory validation. 13 Administrative databases were linked deterministically using encrypted unique confidential codes that preserved patient confidentiality. The authors first linked the CorHealth Ontario registry (date and type of cardiac procedures, left ventricular function data) with the ICES Congestive Heart Failure database to classify patients with CABG by EF and HF status. The database is derived from physician billings based on either 1 documented admission for HF alone or 1 outpatient claim for HF that was followed by at least 1 additional outpatient HF claim within 1 year. This algorithm was validated in primary care patient records and shown to have 85% sensitivity and 97% specificity in identifying HF events.
14 These data were then linked to the Canadian 
Clinical Perspective
What Is New?
• In a population-based retrospective cohort study of patients undergoing isolated primary coronary artery bypass grafting, we observed a higher prevalence of heart failure with preserved ejection fraction in women.
• In addition, both the operative and long-term mortality rates were higher in women with heart failure with preserved ejection fraction.
What Are the Clinical Implications?
• Our findings highlight the need for a paradigm shift in Western countries to improve the preoperative screening of heart failure symptoms, regardless of ejection fraction.
• Specifically, further studies are required to incorporate heart failure into cardiac surgical mortality prediction scores.
• Women and men with heart failure with preserved ejection fraction should be the target of extended postoperative follow-up and personally tailored interventions. Adjusted Clinical Groups frailty-defining diagnoses indicator, which is an instrument designed and validated for research of frailty-related outcomes and resource utilization using administrative data.
Classification of HF by Left Ventricular Function
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Outcome
The primary outcome was death from any cause. We confirmed in-hospital mortality using the DAD and postdischarge mortality using RPDB.
Statistical Analysis
L.Y.S. and A.B.E. had full access to all of the data in the study and take responsibility for its integrity and for the data analysis. All analyses were performed in the overall cohort and then stratified by sex. Continuous variables were expressed as mean (SD) and categorical variables as number (proportions). Mortality was assessed at 30 days postoperatively and through March 31, 2016. Patients were censored at the front end when they lost possession of a valid Ontario health insurance card for 2 consecutive eligibility quarters (ie, have left the province of Ontario). Survival time was defined as date of index surgery until date of death or date of last follow-up. Event rates in each group were calculated using the Kaplan-Meier method and presented graphically, with the significance of differences in mortality between groups assessed using the log-rank test. Sex-specific longterm mortality rates were standardized by age, and pooled long-term mortality rates were standardized by age and sex using the 2011 Canadian population as the reference. The risk of death was assessed using Cox proportional hazard models with multivariable adjustment. We explored the modifying effect of sex and identified sex-specific risk factors for long-term mortality using multiplicative interaction terms. We performed 2 sensitivity analyses. First, we used generalized estimating equations to determine the adjusted association of patient-level characteristics with 30-day and long-term mortality while accounting for clustering of patients within hospitals. 28 Next, we added completeness of revascularization to this generalized estimating equations model to evaluate the impact of incomplete revascularization on early and long-term mortality. Incomplete revascularization was defined as presence of ≥1 ungrafted vessels with ≥70% stenosis in the left anterior descending, circumflex, or right coronary artery territories. The measure of association was hazard ratios (HRs) with 95% confidence intervals (CIs). Analyses were performed using SAS 9.3 (SAS Institute), with statistical significance defined by a 2-sided P value of <0.05. Of all patients with HFpEF, 873 (31.7%) were women. Women with HFpEF were more likely than men to be older, of lower income status, to undergo emergent surgery, and to have comorbidities such as recent myocardial infarction (MI), hypertension, COPD/asthma, diabetes mellitus, hypothyroidism, and anemia, but less likely to have undergone percutaneous coronary intervention (PCI) or to have remote MI, atrial fibrillation, morbid obesity, chronic renal disease, and dialysis (Table 2) .
Results
Prevalence of pEF and rEF
Of all patients with HFrEF, 1090 (22.6%) were women. Women with HFrEF were more likely than men to be older, to be of slightly lower income status, to undergo emergent surgery, and to have comorbidities such as recent MI, hypertension, COPD/asthma, diabetes mellitus, hypothyroidism, and anemia, but less likely to have had a remote MI, atrial fibrillation, and morbid obesity ( Table 2) . Rates of previous PCI were no different between women and men with HFrEF.
30-Day Mortality
The proportion of deaths at 30 days was highest in patients with HF, especially in those with HFrEF (5.1%; 244 of 4816 patients). Kaplan-Meier survival estimates for each of these groups are illustrated in Figure 2 . At 30 days, 90 patients (3.3%) with HFpEF died; this was nearly 5-fold the proportion of deaths in the group with pEF but no HF (0.7%) and 2.5-fold that of the group with rEF but no HF (1.3%; Table 3 ). Similarly, the adjusted risks of 30-day mortality were higher in patients with HF. After multivariable adjustment of all variables listed in with a higher risk of early mortality (adjusted HR, 1.24; 95% CI, 1.06-1.46). Table 3 and Figure 3 summarize the mortality statistics in men and women. Overall, there was a higher proportion of deaths in women than men in the early postoperative period. Women with HFpEF had double the mortality rate compared with their male counterparts, while women with HFrEF had a mortality rate that was 1.5-fold that of men. After multivariable adjustment, the early mortality risk was 2.89 (95% CI, Sex modified the correlation between past PCI and 30-day mortality (Table 5) . Specifically, a history of PCI was correlated with an increased mortality risk in women (adjusted HR, 1.84; 95% CI, 1.30-2.61) but not in men (adjusted HR, 0.89; 95% CI, 0.67-1.18). 
Long-Term Mortality
The mean follow-up period was 4.0AE2.0 years. The median follow-up time was 3.9 years (interquartile range, 2.3-5.6).
The maximum follow-up period was 7.5 years. Table 3 summarizes the mortality rates and adjusted HRs in men and women, while Figure 5 demonstrates the estimated long-term survival stratified by sex. Women with HFrEF had higher standardized long-term mortality rates than men. While the adjusted HRs for long-term mortality were similar between the sexes in the HFpEF subgroup, women with HFrEF had a slightly lower risk of death compared with men. Sex modified the correlation between long-term mortality and age, recent MI, COPD/asthma, and anemia (Table 5) . There was no sex-based difference in long-term mortality in patients younger than 75 years. Although age older than 75 years was associated with a higher risk of death in both sexes, this risk was higher in men compared with women. In addition, COPD/asthma were associated with a higher mortality risk in men, while recent MI and anemia were associated with higher mortality risk in women.
As a post hoc analysis to investigate factors that contributed to poorer outcomes in women, we examined the sex differences in HF onset and severity before and following CABG (Table 7) . We found that women had higher rates of HF admissions before CABG and experienced significantly longer intervals from onset of HF symptoms until CABG compared with men. In the year following CABG, women had significantly higher rates of MI, repeat revascularization, stroke, new-onset dialysis, HF admission, and admission to long-term care facilities compared with men.
Discussion
This population-based study found that a history of HF was a more important prognosticator than EF in patients with CABG.
Four main findings were derived from this study. (1) The prevalence and long-term mortality rates of HF were higher in women than men. (2) Women had a higher adjusted risk of 30-day and long-term mortality compared with men. (3) A history of PCI was correlated with an increased risk of 30-day mortality in women but not in men. For long-term mortality, age 75 years and older and COPD/asthma were associated with increased risk in men, while recent MI and anemia were associated with increased risk in women. (4) Women had higher rates of HF admissions in the year leading up to CABG and experienced a longer delay from HF onset until revascularization when compared with men.
Sex Differences in HF Prevalence and Mortality
Our investigation is the first population-based study to address the sex differences in HFpEF prevalence and outcomes in patients with CABG. Congruent with previous reports, we found a greater proportion of women in the HFpEF subgroup (31.7%) than the HFrEF subgroup (22.6%). 5, 6, 11 Studies of hospitalized patients with HF found that HFpEF contributed to nearly half of the HF cases and was nearly as fatal as HFrEF. 5, 6 In our study, the overall prevalence of HFpEF was only half that of HFrEF. Our finding possibly suggests the presence of a natural selection bias, whereby patients with CABG were more likely to present with HFrEF as a result of CAD being a stronger risk factor for HFrEF than HFpEF. However, we cannot rule out the possibility of under- recognition of the HFpEF syndrome in the perioperative setting.
In addition, we found that in the HFpEF group, the 30-day mortality rate was higher in women than men. This is an important observation as nearly 50% of all HF cases occur in women, but HF in women remains a poorly recognized and understood syndrome. 29 Despite better outpatient survival from HF in women compared with men, we found this pattern to be reversed in the perioperative setting, especially in those with preserved EF. Our post hoc analysis further characterized HF by sex in surgical patients. We found that women had higher rates of acute HF admissions both within 90 days and 1 year before CABG. In addition, there was a longer delay from HF onset until CABG in women compared with men. These findings suggest that in addition to potential delay in definitive treatment of ischemic heart disease, women likely also present with more advanced stages of HF at the time of surgery, which would naturally have an impact on their post-CABG survival. Our findings also suggest that regardless of HF status, there was a higher rate of complications in women that had not only led to poorer survival but also had implications on their quality of life.
There is therefore an urgent need for improved recognition of the sex differences in HF presentation 30 and research to inform tailored perioperative management and follow-up. CAD is a leading cause of HF for both sexes. The severity of CAD is often underestimated in women compared with men, possibly because of the likelihood for an atypical presentation to CAD for women. 31 When diagnosed with CAD, women are less likely than men to undergo cardiac catheterization and revascularization. 32 This is an important observation, especially since patients with HFpEF with incomplete revascularization displayed greater deterioration in EF and increased mortality. 8 Notably, the better prognosis of HFpEF observed in the current study is likely in part caused by a higher proportion of the HFpEF group having previous PCIs than the HFrEF group. In a small study of patients with HFpEF with CAD, those who underwent CABG had similar short-term mortality but better long-term survival than those who underwent PCI. 12 This study and ours support the importance of timely revascularization in women with HFpEF. We found that the adjusted risk of mortality differed in HFpEF versus HFrEF, especially over the short term. These findings are congruent with the Swedish CABG study, 11 HFrEF is a well-recognized risk factor for short-and long-term mortality after CABG surgery, [2] [3] [4] 11 although the prognostic role of sex is still poorly understood in this group. A post hoc analysis of the IMAGINE (Ischemia Management With Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme) trial found female sex to be a nonsignificant predictor of death after multivariable adjustment and concluded that definitive answers regarding sex differences in long-term outcomes after CABG should come from future pooling of studies comprising a larger number of women. 34 Our study provides, so far, the largest cohort to evaluate the differences in CABG outcomes in men and women with rEF. We found that although the short-and longterm mortality rates were higher in women, the adjusted risk of death was lower in women with HFrEF and similar between the sexes in rEF without HF. This possibly reflects the longer life expectancy in women, as well as the widespread recognition of the importance of HFrEF management in the perioperative period and in long-term follow-up.
EF and Perioperative Management
Perioperative risk stratification and management have been "EF-centric," with much attention being dedicated to the optimization of rEF. 
Limitations
This study has several limitations. First, the sex differences in outcomes by HF status are representative of perioperative practice in Ontario. Similar research needs to be conducted in other settings to confirm the generalizability of our findings. Second, our data sources lacked some relevant detailed information such as smoking history. The inability to measure, and thereby adjust for, differences in such characteristics could have explained, in part, the differences in mortality rates observed in this study. Third, the lack of natriuretic peptides measurements precluded the use of this biomarker as a third diagnostic criterion for HFpEF 7 and possibly contributed to misclassification of HFpEF as pEF without HF. However, biomarker measurements are not a routine practice in Ontario, and whether BNP would further improve risk stratification in patients with HF, above and beyond physician-diagnosed HF, remains to be determined. Fourth, our reporting of sex-specific risk factors is to be interpreted in the context of multiple testing. Finally, cohort studies are by nature subject to residual confounding.
Conclusions
In a large cohort of patients who underwent primary CABG, we found a higher prevalence of HFpEF in women and a higher risk of operative mortality in women compared with men with HFpEF. HFpEF is an important predictor of operative and longterm mortality. Rather than being "EF-centric," efforts should be given to earlier recognition of HF symptoms in women and timely referral of these patients for revascularization. Similarly, perioperative risk stratification and extended postoperative follow-up including tailored therapy and home monitoring should be focused on women and men with signs and symptoms of HF rather than on reduced EF alone.
